Carl Zeiss Meditec: Acri.Tec Takeover Closed

Jena, Germany, Oct 2, 2007 - (Hugin via Asia Business News) - Acquisition rounds off product portfolio for innovative implants - Market position in Germany considerably stronger Jena, 02 October 2007 - Medical technology provider Carl Zeiss Meditec AG (ISIN: DE 0005313704), listed on the TecDAX of German Stock Exchange, announced today that the recently announced acquisition of Acri.Tec AG has been closed yesterday afternoon. The corresponding contractually agreed conditions, which included the approval of the German anti-trust authority, have been fulfilled. "Now that the formal conditions have been fulfilled, we will be focusing all our efforts on integrating Acri.Tec into Carl Zeiss Meditec," said Ulrich Krauss, President and CEO of Carl Zeiss Meditec AG. "We want to achieve our goal of an uniform market presence as quickly as possible." Acri.Tec AG, which generated sales revenues in financial year 2006 to the amount of € 15.4 million, specialises in innovative implants for ophthalmic surgery (intraocular lenses, IOL) and other products (viscoelastic solutions and products for vitreoretinal surgery). The two companies' products complement each other extremely well. This acquisition will expand Carl Zeiss Meditec's offering in the rapidly-growing ophthalmic surgery segment. It now covers the entire spectrum of intraocular lenses - ranging from simple monofocal intraocular lenses for the treatment of cataracts to technologically sophisticated multifocal and micro-incision lenses for refractive surgery. Carl Zeiss Meditec is also a leading global provider of ophthalmic devices for the diagnosis, treatment and aftercare of cataracts. Furthermore, the acquisition of Acri.Tec will strengthen Carl Zeiss Meditec's business in Germany into the long-term. "The acquisition of Acri.Tec shows that we are consistently developing our market position in ophthalmic surgery and continuing to make investments here. That will remain so in the future: Building on our wider foundations, we will significantly accelerate our innovation in this area. This acquisition is another important milestone in the expansion of our position in ophthalmology which, in addition to neuro- and ENT surgery, represents one of the key pillars of Carl Zeiss Meditec's business", concludes Krauss.

Contact Jens Brajer/ Director Investor Relations Goeschwitzer Straße 51-52 07745 Jena, Germany Telefon: +49 (0) 36 41 - 2 20 - 1 05 Telefax: +49 (0) 36 41 - 2 20 - 1 17 E-Mail: investors@meditec.zeiss.com Web: http://www.meditec.zeiss.com

--- End of Message ---

Carl Zeiss Meditec AG Goeschwitzer Strasse 51-52 Jena Germany

WKN: 531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share, TecDAX; Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Geregelter Markt in Frankfurter Wertpapierbörse;

Copyright © Hugin ASA 2007. All rights reserved.

Carl Zeiss Meditec AG

www.meditec.zeiss.com

ISIN: DE0005313704

Stock Identifier: XFRA.AFX